Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children. by Seale, Anna C et al.
Seale, AC; Bianchi-Jassir, F; Russell, NJ; Kohli-Lynch, M; Tann, CJ;
Hall, J; Madrid, L; Blencowe, H; Cousens, S; Baker, CJ; Bartlett, L;
Cutland, C; Gravett, MG; Heath, PT; Ip, M; Le Doare, K; Madhi,
SA; Rubens, CE; Saha, SK; Schrag, SJ; Sobanjo-Ter Meulen, A; Veke-
mans, J; Lawn, JE (2017) Estimates of the Burden of Group B Strep-
tococcal Disease Worldwide for Pregnant Women, Stillbirths, and
Children. Clinical infectious diseases, 65 (suppl2).S200−S219.ISSN1058−
4838DOI : https : //doi.org/10.1093/cid/cix664
Downloadedfrom : http : //researchonline.lshtm.ac.uk/4645824/
DOI : 10.1093/cid/cix664
Clinical Infectious Diseases
S200 • CID 2017:65 (Suppl 2) • Seale et al
Clinical Infectious Diseases®  2017;65(S2):S200–19
Estimates of the Burden of Group B Streptococcal Disease 
Worldwide for Pregnant Women, Stillbirths, and Children
Anna C. Seale,1,2 Fiorella Bianchi-Jassir,1 Neal J. Russell,1,3 Maya Kohli-Lynch,1,4 Cally J. Tann,1,5 Jenny Hall,6 Lola Madrid,1,7 Hannah Blencowe,1 Simon 
Cousens,1 Carol J. Baker,8 Linda Bartlett,9 Clare Cutland,10 Michael G. Gravett,11,12 Paul T. Heath,13 Margaret Ip,14 Kirsty Le Doare,13,15  
Shabir A. Madhi,10,16 Craig E. Rubens,11,17 Samir K. Saha,18 Stephanie J. Schrag,19 Ajoke Sobanjo-ter Meulen,20 Johan Vekemans,21 and Joy E. Lawn1
1Maternal, Adolescent, Reproductive and Child Health Centre, London School of Hygiene & Tropical Medicine, United Kingdom; 2College of Health and Medical Sciences, Haramaya University, Dire 
Dawa, Ethiopia; 3King’s College London, United Kingdom; 4Centre for Child and Adolescent Health, School of Social and Community Medicine, University of Bristol, United Kingdom; 5Neonatal Medicine, 
University College London Hospitals NHS Foundation Trust, United Kingdom; 6Department of Reproductive Health Research, University College London Institute for Women’s Health, United Kingdom; 
7ISGlobal, Barcelona Centre for International Health Research, Hospital Clinic, University of Barcelona, Spain; 8Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of 
Medicine, Houston, Texas; 9Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 10Medical Research Council: Respiratory and Meningeal Pathogens 
Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South 
Africa; 11Global Alliance to Prevent Prematurity and Stillbirth, Seattle, Washington; 12Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle; 13Vaccine Institute, 
Institute for Infection and Immunity, St George’s University of London and St George’s University Hospitals NHS Foundation Trust, United Kingdom; 14Department of Microbiology, Faculty of Medicine, 
Chinese University of Hong Kong; 15Centre for International Child Health, Imperial College London, United Kingdom; 16National Institute for Communicable Diseases, National Health Laboratory Service, 
Johannesburg, South Africa; 17Department of Global Health, University of Washington, Seattle; 18Bangladesh Institute of Child Health, Dhaka; 19National Center for Immunization and Respiratory Diseases, 
Centers for Disease Control and Prevention, Atlanta, Georgia; 20Bill & Melinda Gates Foundation, Seattle, Washington; and 21World Health Organization, Geneva, Switzerland
Background. We aimed to provide the first comprehensive estimates of the burden of group B Streptococcus (GBS), including inva-
sive disease in pregnant and postpartum women, fetal infection/stillbirth, and infants. Intrapartum antibiotic prophylaxis is the cur-
rent mainstay of prevention, reducing early-onset infant disease in high-income contexts. Maternal GBS vaccines are in development.
Methods. For 2015 live births, we used a compartmental model to estimate (1) exposure to maternal GBS colonization, (2) cases 
of infant invasive GBS disease, (3) deaths, and (4) disabilities. We applied incidence or prevalence data to estimate cases of maternal 
and fetal infection/stillbirth, and infants with invasive GBS disease presenting with neonatal encephalopathy. We applied risk ratios 
to estimate numbers of preterm births attributable to GBS. Uncertainty was also estimated.
Results. Worldwide in 2015, we estimated 205 000 (uncertainty range [UR], 101 000–327 000) infants with early-onset disease 
and 114 000 (UR, 44 000–326 000) with late-onset disease, of whom a minimum of 7000 (UR, 0–19 000) presented with neonatal 
encephalopathy. There were 90 000 (UR, 36 000–169 000) deaths in infants <3 months age, and, at least 10 000 (UR, 3 000–27 000) 
children with disability each year. There were 33 000 (UR, 13 000–52 000) cases of invasive GBS disease in pregnant or postpartum 
women, and 57 000 (UR, 12 000–104 000) fetal infections/stillbirths. Up to 3.5 million preterm births may be attributable to GBS. 
Africa accounted for 54% of estimated cases and 65% of all fetal/infant deaths. A maternal vaccine with 80% efficacy and 90% cov-
erage could prevent 107 000 (UR, 20 000–198 000) stillbirths and infant deaths.
Conclusions. Our conservative estimates suggest that GBS is a leading contributor to adverse maternal and newborn outcomes, 
with at least 409 000 (UR, 144 000–573 000) maternal/fetal/infant cases and 147 000 (UR, 47 000–273 000) stillbirths and infant 
deaths annually. An effective GBS vaccine could reduce disease in the mother, the fetus, and the infant.
Keywords. group B Streptococcus; infection; newborn; stillbirth; maternal. 
The number of worldwide child deaths has declined, from 
an estimated 12.7 million in 1990 to 5.9 million in 2015 [1]. 
However, there has been less progress in reducing neonatal 
mortality and stillbirths, with 2.7 million neonatal deaths and 
2.6 million stillbirths in 2015 [2, 3]. Maternal mortality remains 
unacceptably high, with an estimated 303 000 deaths in 2015. 
Most of this burden is in low-income settings, particularly in 
sub-Saharan Africa and South Asia [1, 2, 4].
Infection is an important cause of maternal, fetal, and 
infant mortality in low- and middle-income contexts [1, 5–7]. 
However, in addition to the substantial burden of mortal-
ity, there is a mostly unquantified burden of infection-related 
short- and long-term morbidity [8]. Infections are also an 
important underlying contributor to preterm birth and neo-
natal encephalopathy, which, along with infections, are leading 
causes of neonatal mortality and subsequent adverse outcomes 
worldwide [8–11].
Understanding of specific infectious etiologies is, however, 
limited [12]. Quantifying the burden of individual etiologies 
is necessary to inform public health interventions. Group B 
Streptococcus (GBS) is an important perinatal pathogen [13, 
14], yet to date no systematic estimates have been undertaken 
of its overall global burden [15].
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GBS is a frequent colonizer of the maternal gastrointestinal 
and genital tracts. Overall, 18% (95% confidence interval [CI], 
17%–19%) of women worldwide are estimated to be colonized, 
although there is regional variation in prevalence, ranging from 
a high prevalence in the Caribbean of 35% (95% CI, 35%–40%), 
to a much lower prevalence in Southern Asia and Eastern Asia 
(13% [95% CI, 10%–14%] and 11% [95% CI, 10%–12%], respec-
tively) [16]. Ascending infection can cause maternal, fetal, and 
early-onset neonatal disease (days 0–6), leading to maternal 
death, stillbirth, and/or neonatal death [17–19]. In survivors 
of neonatal or young infant GBS disease, neurodevelopmen-
tal impairment may result [20]. In addition to causing invasive 
neonatal disease, maternal GBS colonization also increases the 
risk of preterm birth [21]. Neonatal encephalopathy (NE) may 
occur with invasive GBS disease, but maternal GBS coloniza-
tion and ascending infection also increases the risk of NE [22].
Preventive measures aimed at reducing the risk of invasive 
early-onset GBS disease (EOGBS) in newborns have focused 
on intrapartum antibiotic prophylaxis (IAP), with intravenous 
antibiotics given to women in labor, based either on microbi-
ological screening or clinical risk factors [23]. However, this 
depends on national policy and a health system with the capacity 
to implement either strategy with appropriate coverage. While 
reductions in EOGBS disease (days 0–6 after birth) in the United 
States have been observed [24], IAP does not prevent late-onset 
GBS disease (LOGBS; days 7–89) [25] and is unlikely to have 
an impact on stillbirth or preterm birth. GBS vaccines are in 
development [26] and, if given to women, could be effective in 
preventing these outcomes as well as infant and maternal inva-
sive GBS disease [15]. Vaccine candidates include protein-based 
formulations and serotype-specific polysaccharide-protein con-
jugates [27] and thus an understanding of serotype distribution 
in maternal and infant disease worldwide is important.
This is the last article in a supplement estimating the burden 
of invasive GBS disease in pregnant and postpartum women, 
stillbirths, and infants (Figure  1) [15]. The supplement 
includes systematic reviews and meta-analyses across the dis-
ease burden schema (Figure 2). These provide input parame-
ters into the compartmental model described here, for infant 
GBS cases, deaths, and disability (Figure 3). We also estimate 
maternal GBS disease, stillbirths with GBS disease, the subset 
of cases of infant GBS disease who also have neonatal enceph-
alopathy, and preterm birth attributable to GBS. These are 
reported according to international guidelines [28, 29].
OBJECTIVES
We aimed to:
1. Estimate national, regional, and worldwide numbers of 
infants in 2015 with invasive GBS disease (including those 
presenting with neonatal encephalopathy), and outcomes in 
terms of deaths and disability, using a compartmental model.
Figure 1. Overview of the articles in this supplement to estimate the worldwide burden of group B Streptococcus. Adapted from Lawn et al [15]. Abbreviations: GBS, group 
B Streptococcus; NE, neonatal encephalopathy.
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Figure 2. Disease schema for outcomes of maternal group B Streptococcus colonization showing worldwide estimates for 2015. Adapted from Lawn et al [15]. Abbreviations: 
GBS, group B Streptococcus; NE, neonatal encephalopathy.
Figure  3. Compartmental model for estimating cases of infant group B streptococcal disease, deaths, and disability. Abbreviations: EOGBS, early-onset group B 
Streptococcus; GBS, group B Streptococcus; IAP, intrapartum antibiotic prophylaxis; LOGBS, late-onset group B Streptococcus.
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2. Estimate national, regional, and worldwide numbers of cases 
in 2015, using pooled estimates of incidence, proportions or 
risk ratios, derived from meta-analyses for:
a. maternal GBS disease,
b. stillbirths with invasive GBS disease, and
c. Preterm birth attributed to maternal GBS colonization.
3. Estimate the number of maternal and infant cases, infant 
deaths, and stillbirths currently prevented by IAP, and pre-
ventable cases and deaths with high worldwide IAP coverage 
and/or maternal GBS vaccination.
4. Describe GBS serotypes colonizing mothers and causing 
maternal and infant GBS disease, summarizing reported 
regional variation.
METHODS
We summarize our methods according to our 4 objectives as 
follows:
1. Estimate national, regional, and worldwide numbers of 
infants in 2015 with invasive GBS disease (including those 
presenting with neonatal encephalopathy) and outcomes in 
terms of deaths and disability, using a compartmental model.
Modeling Approach
We conceptualized the full burden of GBS disease (Figure 2) to 
include pregnant and postpartum women, fetal infections (based 
on stillbirths), and infants, as described in the first article in this 
supplement [15]. We took a compartmental model approach to 
modeling infant invasive GBS disease, deaths, and disability, with 
4 steps as illustrated in Figure 3. For the first step in the model 
(maternal GBS colonization), the step where most data were 
available for national prevalence estimation, we also attempted a 
multivariable regression model to predict national maternal GBS 
colonization, as an alternative to using a subregional estimate 
when national-level data were limited (Appendix).
Data Inputs
We sought data inputs from the published literature through sys-
tematic reviews and unpublished sources through research data-
bases and investigators worldwide, as summarized in the previous 
10 articles (Figure 1). The specific methods used for each of these 
(database searches, inclusion and exclusion criteria, data charac-
teristics, criteria used to assess bias and sensitivity analyses) are 
described in general [15] and reported elsewhere [16–23, 30]. We 
performed meta-analyses, to obtain estimates of maternal GBS col-
onization prevalence [16], the ratio of late-onset to early-onset inva-
sive GBS disease [19], case fatality risks (CFRs) [19], proportion of 
cases with meningitis [19], proportion of infants with GBS menin-
gitis who had moderate to severe neurodevelopmental impairment 
[20], incidence of maternal GBS disease in pregnant/postpartum 
women [17], prevalence of GBS disease in stillbirth [18], prev-
alence of GBS disease in neonatal encephalopathy [22], and the 
association between maternal GBS colonization and preterm birth 
[21]. We calculated pooled estimates using random-effects models 
[31] to allow for heterogeneity across studies by use of a statistical 
parameter representing the variation between studies.
Burden Estimation Applying the Compartmental Model
Step 1. Exposure to Maternal Group B Streptococcus Colonization
For the first step of the compartmental model, we determined 
maternal GBS colonization prevalence for countries, subregions 
(South America, Central America, Caribbean, Western Asia, 
Southern Asia, South-Eastern Asia, Eastern Asia, Oceania) and 
regions (Latin America, Asia, Africa, Oceania, developed) as 
described elsewhere [16], to apply to estimates of live births in 
195 countries for 2015, using latest United Nations data [32]. 
The colonization data were adjusted for sampling site (rectal 
and/or vaginal) and laboratory culture methods [16]. Where 
data were considered sufficient (≥1000 mothers tested for 
rectovaginal colonization), we used an estimate for individual 
countries. Where data were limited (<1000 mothers tested for 
rectovaginal colonization), we used a subregional estimate, and 
where no subregional estimate was available, we used a regional 
estimate (Supplementary Table 1 for inputs by country).
Step 2. Cases of Invasive Early-Onset Disease and Late-Onset 
Disease in Different Intrapartum Antibiotic Prophylaxis Settings
For the second step of the compartmental model, we assessed 
IAP policies and their implementation in countries as described 
elsewhere in this supplement [23], and categorized 89 countries 
with data available into 1 of 4 categories, which were (1) micro-
biological screening for maternal GBS colonization with IAP and 
high implementation coverage (>50% of mothers screened and 
given IAP if appropriate); (2) clinical risk factor approach with 
IAP given to mothers with risk factors before delivery and high 
implementation coverage (>50% with risk factors receiving IAP); 
(3) microbiological screening for maternal GBS colonization 
with IAP and low implementation coverage (<50%); (4) clinical 
risk factor approach with IAP given to mothers with risk factors 
before delivery and low implementation coverage (<50%), or no 
IAP strategy in place. We assigned countries in the developed 
region with no data to category 1 as a conservative approach, and 
of those countries reporting these data, 21 of 31 developed coun-
tries were in group 1. We assigned countries, not in the developed 
region and with no data to group 4, as 51 of 59 countries not in 
the developed region reporting these data were in this group.
We then assessed the risk of EOGBS disease in studies 
reporting maternal GBS colonization data, and the use of IAP, 
as described elsewhere in this supplement [30]. We used the 
linear association between IAP use and risk of EOGBS disease 
described in [23] to estimate the risk of EOGBS disease in each 
of the 4 contexts, with specific risks for each group as follows: 
group 1 = 0.3% (95% CI, .0–.9%); group 2 = 0.6% (95% CI, .10%–
1.2%); group 3 = 0.9% (95% CI, .4%–1.5%); group 4 = 1.1% (95% 
CI, .6%–1.5%). For each country, the number of cases of EOGBS 
was estimated by multiplying the estimated number of exposed 
babies by the appropriate risk for that country.
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We used regional estimates of the ratio of early-onset to 
late-onset GBS cases [19] to then estimate the number of LOGBS 
cases. For Oceania, where data were lacking, we applied the esti-
mate for Asia, as the most similar regional context. There were 
variations in estimates, with the highest ratio in Asia (5.99 [95% 
CI, 2.40–14.9]) suggesting more EOGBS than LOGBS, and low-
est in Africa (1.02 [95% CI, 0.82–1.27]). We give parameters for 
each region in Table 1. These regional estimates could, however, 
be affected by low case ascertainment. This could reduce EOGBS 
disease cases, particularly those with home delivery, inadequate 
access to care and/or high rapid CFR, and/or late-onset cases, 
particularly if cerebrospinal fluid sampling is not undertaken, 
and cases of GBS meningitis are thus not detected. We therefore 
did a sensitivity analysis applying a worldwide ratio of early-on-
set to late-onset GBS disease from high-quality studies world-
wide (1.11 [95% CI, 0.90–1.30] / 3.92) [19].
Step 3. Deaths in Early-Onset and Late-Onset Group B 
Streptococcus Disease
For the third step of the compartmental model, we applied 
region-specific CFRs to 3 different groups that differ consid-
erably in terms of outcome: EOGBS cases delivered without a 
skilled birth attendant, EOGBS cases delivered with a skilled 
birth attendant, and LOGBS cases.
Case fatality risk for EOGBS: We applied percentages of skilled 
birth attendance for each country to EOGBS cases to determine 
EOGBS cases which would, and would not, have been attended 
by a skilled birth attendant. We applied a CFR of 0.9 (0.3–1.0) 
to estimated EOGBS cases born without a skilled birth attend-
ant, based on expert opinion as to the likely high CFR in these 
“unseen” cases. To estimate deaths from EOGBS born with a 
skilled birth attendant (and for all developed countries), we esti-
mated regional CFRs for EOGBS from facility-based data, as 
described elsewhere in this supplement [19]. We applied these 
regional CFRs to cases of EOGBS disease with skilled birth 
attendance. The highest CFR for EOGBS with skilled attend-
ance was in Africa (0.27 [0.15–0.37]), then Latin America (0.17 
[0.05–0.30]), Asia (0.14 [0.06–0.23]), and developed countries 
(0.05 [0.04–0.07]) (Table 1). For Oceania, where even regional 
data were lacking, we applied the risk in Asia, being the most 
geographically proximal.
Case fatality risk for LOGBS: We also estimated regional CFRs 
for LOGBS from facility-based data, as described elsewhere in 
this supplement [19]. Regional CFRs for LOGBS were lower 
than EOGBS overall, with the highest again in Africa (0.12 
[0.05–0.19]) (Table 1). Due to insufficient data from Oceania, 
we applied the CFR for Asia.
Step 4. Disability or Impairment After Infant Group B Streptococcus 
Meningitis
We estimated moderate to severe neurodevelopmental 
impairment (NDI) after meningitis, only, because data were 
insufficient to estimate NDI after sepsis, as described else-
where in this supplement [20]. To do this, we applied the per-
centage of infant cases of GBS disease which were meningitis, 
for early (12% [8%–15%]) and late-onset (42% [30%–55%]) 
GBS disease [18] to estimates of EOGBS and LOGBS survi-
vors. We then applied an incidence risk of moderate to severe 
NDI at 18 months of age of 0.18 (0.13–0.22) [20]. These data 
were limited to developed countries; however, we applied this 
proportion worldwide, on the basis that this would be a mini-
mum estimate as NDI was unlikely to be lower in settings with 
reduced levels of care.
Triangulation of Infant Invasive Group B Streptococcus Disease Cases 
From the Compartmental Model With Estimates Based on Incidence Data
We compared the results from the compartmental model for 
infant GBS disease cases with those estimated using incidence 
data on infant GBS disease [19]. To do this, we calculated subre-
gional incidence, or regional incidence where subregional data 
were not available, of EOGBS and LOGBS disease. We applied 
these to estimates of live births for each country in 2015. Data 
inputs are given for each country in Supplementary Table 2.
Infants With Invasive Group B Streptococcus Disease Presenting With 
Neonatal Encephalopathy
To calculate the numbers of infants with invasive GBS disease 
and coexistent neonatal encephalopathy, we used previously 
published national incidences of neonatal encephalopathy and 
modeled uncertainties and adjusted these for births in 2015 
[11]. Then using our new data, we calculated the proportion 
of invasive GBS disease among these cases of NE. In developed 
countries, among all NE cases included in cooling trials, 0.51% 
(95% CIs, 0.05%–0.97%) were also identified as having GBS dis-
ease [22]. Data inputs were limited for data from other regions 
(3/16 studies), so we used the worldwide estimate of 0.58% (95% 
CIs, 0.18%–0.98%) of NE cases with GBS disease to apply in 
Africa, Asia, Latin America, and Oceania. Since our case defin-
ition assumes that cases of NE with GBS count as a case of GBS 
invasive disease, we include these numbers within our estimates 
of GBS infant disease.
2. Estimate country, regional, and worldwide number of cases 
of GBS-associated maternal disease, stillbirths, and preterm 
birth, for births in 2015 using pooled estimates of incidence, 
proportions, or risk ratios, derived from meta-analyses.
Where a compartmental approach was not possible, we used 
incidence, prevalence, or risk ratios from pooled data applied 
to births in 2015 to make minimum estimates of worldwide, 
regional, and national estimates for cases attributable to GBS 
(Figure 2).
a. Maternal GBS disease
We calculated the pooled incidence of maternal GBS disease 
per 1000 maternities and applied this to a denominator of total 
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births worldwide to estimate cases. As described elsewhere [17], 
data were only available for developed countries, with a pooled 
estimate of 0.23 (95% CI, .09–.37) per 1000 maternities. We 
applied this to all regions, on the basis that maternal GBS disease 
was unlikely to be lower in settings with reduced levels of care.
b. Stillbirths with GBS disease
We calculated the pooled prevalence of GBS disease in stillbirths, 
equating also to the minimum number of fetal infections. Data 
were available from developed countries (1% [95% CIs, 0–2%]) 
and from Africa (4% [95% CIs, 2%–6%]) [18]. For regions with 
no data, we applied the prevalence of GBS in stillbirths from 
developed countries, on the basis that GBS-associated stillbirth 
was unlikely to be lower in settings with reduced levels of care. 
However, as this is a conservative approach, we did a sensitivity 
analysis applying the regional estimate from Africa (4% [95% 
CIs, 2%–6%]) [18] to regions with no data.
c)  Preterm birth associated with maternal GBS 
colonization
We calculated pooled risk ratios or odds ratios for the associa-
tion between maternal GBS colonization and preterm birth [21]. 
For cohort or cross-sectional studies, the risk ratio  was  1.21 
(95% CI, .99–1.48; P = .061), and for case-control studies, the 
odds ratio was 1.85 (95% CI, 1.24–2.77; P = .003). However, for 
preterm birth the results, in terms of the association between 
maternal colonization and preterm birth, are susceptible to 
confounding and bias. For preterm birth, we thus give a range 
for the number of cases, based on calculation of the population 
attributable fraction, which could be attributable to GBS given 
maternal GBS colonization [16] and incidence of preterm birth 
[33]. The ranges are based on the range in the 95% CIs of risk 
and odds ratios (1.0–2.8) for the association between maternal 
GBS colonization and preterm birth.
3. Estimate maternal and infant cases, stillbirths, and infant 
deaths, prevented by IAP at present, and preventable cases 
and deaths with high worldwide IAP coverage and/or mater-
nal GBS vaccination.
We applied risks, without adjusting for IAP use, to estimates of 
live births for 2015 to calculate early-onset cases with no IAP 
use. We adjusted for skilled birth attendance as previously and 
applied regional facility CFRs to estimate deaths with no IAP 
use. We subtracted current cases and deaths in early infancy to 
calculate those currently prevented by IAP.
For IAP scale-up worldwide, we assumed that all births 
were being attended by a skilled birth attendant,  able to pro-
vide careful clinical monitoring for risk factors at delivery and 
administer IAP, but we did not adjust CFRs for this. Given these 
assumptions, we applied risks of EOGBS disease with a clinical 
risk factor approach, with coverage >50% and IAP worldwide 
where microbiological screening and IAP was not already in 
place. We did not calculate cases prevented with IAP for preg-
nant or postpartum women or stillbirths, or late-onset cases as 
these are not the target of IAP and any effect is likely to be lim-
ited due to the timing of IAP administration.
For maternal GBS vaccination, we calculated cases prevented 
(with no IAP) by a maternal GBS vaccine with 80% efficacy 
and coverage at 50% and 90%, for births in 2015. No assump-
tions were made on skilled birth attendance and/or laboratory 
capacity.
4. Describe GBS serotypes colonizing mothers and causing 
maternal and infant GBS disease.
We calculated the prevalence of GBS serotypes (Ia/Ib/II–X) col-
onizing mothers and causing maternal and infant GBS disease 
from meta-analyses of proportions of each serotype reported in 
each disease syndrome [16, 17, 19]. We calculated the coverage 
of a pentavalent maternal GBS vaccine (Ia/Ib/II/III/V) based on 
these data.
Uncertainty Estimation
For the compartmental model, we included uncertainty at 
every step by taking 1000 random draws, assuming a normal 
distribution with a mean equal to the point estimate of the 
parameter, and standard deviation (SD) equal to the estimated 
standard error (SE) of the parameter. We present the 2.5th and 
97.5th centiles of the resulting distributions as the uncertainty 
range (UR).
For the incidence or proportional approach, we estimated 
uncertainty around the point estimate with the same approach, 
taking 1000 random draws, assuming a normal distribution with 
a mean equal to the point estimate of the parameter, and SD equal 
to the estimated SE of the parameter. We present the 2.5th and 
97.5th centiles of the resulting distributions as the UR.
Source Code
Code used for the estimation process is available online at 
https://doi.org/10.17037/data.51.
RESULTS
We summarize our results according to our 4 objectives as 
follows:
1. Estimate country, regional, and worldwide cases of invasive 
infant GBS disease, and outcomes in terms of deaths and dis-
abilities for live births in 2015 using a compartmental model.
Step 1. Exposure to Maternal Group B Streptococcus Colonization
We estimated that, of 140 million live births in 2015, there 
were 21.3 million (UR, 16.4–27.0 million) infants exposed to 
maternal GBS colonization at delivery. There were 74.5 mil-
lion live births in Asia with 8.9 million (UR, 6.7–10.7 million) 
infants exposed, 40.7 million live births in Africa with 8.0 mil-
lion (UR, 5.3–10.3 million) infants exposed, 11.0 million live 
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births in Latin America with 2.1 million (UR, 1.7–2.5 million) 
infants exposed, 260 000 live births in Oceania with 33 000 (UR, 
31–36 000) infants exposed and 13.4 million live births in devel-
oped countries with 2.8 million (UR, 2.3–3.2 million) infants 
exposed (subregional estimates in Supplementary Figure 3).
Step 2. Cases of Early-Onset and Late-Onset Disease in Different 
Intrapartum Antibiotic Prophylaxis Settings
We estimated that there were 319 000 cases (UR, 119 000–
417 000) of infant invasive GBS disease worldwide. Most cases 
were EOGBS disease, with 205 000 (UR, 101 000–327 000) cases 
compared to 114 000 (UR, 44 000–326 000) LOGBS cases. With 
a high absolute number of births, and thus newborns exposed, 
Asia had the highest number of EOGBS disease cases, with 
95 000 (UR, 53–143 000). Africa had fewer EOGBS cases 85 000 
(UR, 44–133 000), but, because of the differences in early-on-
set to late-onset disease ratios, more LOGBS disease cases, with 
84 000 (UR, 43–140 000) in Africa compared to 17 000 (UR, 
0–146 000) in Asia. In contrast, developed countries had 11 000 
(UR, 0–26 000) cases of EOGBS and 6000 (UR, 0–15 000) cases 
of LOGBS disease (Table 2; Figure 4; Supplementary Figure 4). 
Using a fixed worldwide ratio of early-onset to late-onset disease 
based only on high-quality studies (sensitivity analysis), we esti-
mated a higher 184 000 (UR, 142–196 000) LOGBS infant cases. 
Asia accounted for this increase, with 84 000 (UR, 65–90 000) 
LOGBS disease cases (Supplementary Figure 5).
Step 3.  Deaths in Early-Onset and Late-Onset Group B Streptococcus 
Disease
We estimated that there were 90 000 (UR, 36 000–169 000) 
deaths in infants due to invasive GBS disease worldwide. 
Africa accounted for 54 000 (UR, 22 000–98 000) of these, Asia 
31 000 (UR, 13 000–60 000), Latin America 4000 (600–10 000), 
Oceania 200 (UR, 60–300), and developed countries 800 (UR, 
0–2000).
In terms of deaths due to EOGBS, there were 51 000 deaths 
(UR, 23 000–89 000) in infants without access to healthcare 
worldwide. There were a further 27 000 (UR, 9000–50 000) deaths 
from EOGBS in facilities in developing countries. In contrast, 
there were 500 (UR, 0–1300) deaths in developed countries from 
EOGBS. In terms of LOGBS deaths, overall deaths were lower, 
with 12 000 (UR, 3–30 000) worldwide. Most of these 10 000 (UR, 
3000–21 000) were in Africa. Regional and subregional estimates 
are given in Table 2 and Supplementary Figure 6 and illustrated 
in Figure 5. Countries with the highest number of cases are not 
always those with the highest number of deaths, as illustrated for 
Nigeria, Ethiopia, and Pakistan (Table 3).
Step 4.  Disability: Calculation of Impairment After Infant Group B 
Streptococcus Meningitis
We estimated that a minimum of 10 000 (UR, 3 000–27 000) infants 
worldwide had moderate to severe NDI after GBS meningitis. Of 
these, more than half were in Africa (6000 [UR, 3000–12 000]), 
with 3000 (UR, 0–11 000) in Asia, 700 (UR, 100–2300) in Latin 
America, 700 (UR, 0–1700) in developed countries, and <100 
(UR, 0–100) in Oceania (Table 4; Supplementary Figure 7).
Triangulation of Infant Invasive Group B Streptococcus Disease 
Cases From the Compartmental Model With Estimates Based on 
Incidence Data
Applying pooled incidences of EOGBS and LOGBS to the 140 
million live births for 2015, we estimated a much lower burden, 
particularly for EOGBS cases, than that estimated using the com-
partmental model. We estimated 51 000 (UR, 23 000–89 000) 
infants with EOGBS and 40 000 (UR, 12 000–75 000) infants with 
LOGBS worldwide (subregional estimates in Supplementary 
Figures 8 and 9). These are likely to be considerable underestimates 
as cases are systematically underascertained, particularly in low- 
and middle-income contexts, as described in Table 2 and Figure 6.
Infants With Invasive Group B Streptococcus Disease Presenting With 
Neonatal Encephalopathy
We estimated that there were a minimum of 7000 (300–19 000) 
infants with invasive GBS disease presenting with neonatal 
encephalopathy. There were an estimated 3400 (UR, 200–9000) 
cases in Asia, 3300 (UR, 100–8600) in Africa, 300 (UR, 0–1200) 
in Latin America, 100 (UR, 0–300) in developed countries, and 
10 (UR, 0–40) in Oceania (subregional estimates are given in 
Supplementary Figure 10).
2. Estimate country, regional, and worldwide cases, for births 
in 2015 using pooled estimates of incidence, proportions, 
or risk ratios, derived from meta-analyses for maternal GBS 
disease, stillbirth with GBS disease, and preterm birth associ-
ated with maternal GBS colonization:
a. Maternal GBS disease
We estimated that there were a minimum of 33 000 (UR, 
13–52 000) cases of maternal invasive GBS disease worldwide. 
Estimates are given by subregion in Supplementary Figure 11 
and region in Table 4.
b. Stillbirth with GBS disease
We estimated that there were a minimum of 57 000 (UR, 12 000–
104 000) cases of stillbirth with GBS disease worldwide, equating 
to a minimum of 57 000 (UR, 12 000–104 000) fetal infections. Of 
these, Africa accounted for 42 000 (UR, 10 000–71 000) and Asia 
13 000 (UR, 1000–30 000) (Supplementary Figure 12 and Table 4). 
Applying the higher regional estimate for Africa to regions where 
there are no data (sensitivity analysis), the number of stillbirths 
with GBS disease was much higher, at 96 000 (UR, 26–168 000) 
worldwide, with Asia accounting for 50 000 (UR, 14 000–87 000) 
of these, almost all the increase (Supplementary Figure 13).
c. Preterm birth attributable to GBS
We estimated that the range of cases of preterm birth attrib-
utable to GBS was 0–3.5 million. The cases of preterm birth 
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attributable to GBS according to each risk ratio (in 0.2 incre-
ments [1.0–2.8]) are given in Supplementary Table 4.
3. Estimate maternal and infant cases, infant deaths, and still-
births prevented by IAP at present, and preventable cases and 
deaths with high worldwide IAP coverage and/or maternal 
GBS vaccination.
Contingent in the limitations in our estimates, we estimated 
that 29 000 infants (UR, 0–51 000) with EOGBS and 3000 (UR, 
0–108 000) infant deaths were prevented by intrapartum anti-
biotic prophylaxis worldwide in 2015. With worldwide appli-
cation of a clinical risk factor–based approach (microbiological 
screening where already in place), and IAP (>50% coverage), 
we estimate that 83 000 (UR, 0–166 000) cases of EOGBS and 
27 000 (UR, 0–110 000) deaths could be prevented worldwide 
(not adjusting CFRs for the changes in skilled birth attend-
ance that IAP administration would require). With world-
wide maternal vaccination (and no IAP assumed), a maternal 
GBS vaccine with 80% efficacy and 50% coverage would pre-
vent 127 000 (UR, 63 000–282 000) infant and maternal GBS 
cases, 23 000 (UR, 6000–42 000) stillbirths, and 37 000 (UR, 
15 000–68 000) infant deaths. A maternal vaccine with the 
same assumptions with 90% coverage would prevent 229 000 
(UR, 114 000–507 000) infant and maternal GBS cases, 41 000 
Table 2. Estimated Cases of Maternal, Fetal, and Infant Group B Streptococcal Disease in 2015
Region Maternal GBS Disease Fetal Infectiona EOGBS Disease LOGBS Disease
Southern Asia 8700 9700 42 500 7600
(4000–14 000) (1200–21 300) (23 000–65 400) (0–57 000)
Eastern Asia 4100 1300 21 900 3900
(1700–6700) (0–2300) (12 700–32 900) (0–30 000)
Central Asia 400 200 2300 400
(200–600) (0–400) (1300–3200) (0–3000)
Western Asia 1300 800 9200 1600
(600–2200) (0–1700) (5100–13 800) (0–12 400)
South-Eastern Asia 2900 1500 19400 3500
(1200–4600) (0–3300) (10 800—28 700) (0–43 200)
Asia 35 900 13 400 95 300 17 000
(7 100–28 100) (1200–29 600) (52800–142 900) (0–145 600)
Oceania 60 40 400 100
(20–100) (0–100) (10 800–28 700) (0–43 100)
Northern Africa 1400 3900 15400 15 000
(600–2300) (1000–6700) (8600–22 400) (8300–24 000)
Southern Africa 300 800 4000 3900
(100–500) (200–1400) (2300–5500) (2300–6000)
Eastern Africa 3300 12 600 26 400 25 900
(1300–4600) (3100–21 700) 15 300–40 300) 14 700–42 700)
Western Africa 3200 18 300 23 500 23 000
(1300–5200) (4500–30 800) (10 200–39 000) (10 300–41 000)
Middle Africa 1400 6300 15 900 15 600
(3300–12 500) (1600–10 800) (7900–25 600) (7500–25 900)
Africa 9600 42 000 85 200 20 700
(6700–25 000) (10 400–71 400) (44 300–132 800) (43 100–140 000)
Caribbean 200 100 2600 1300
(60–300) (0–200) (1500–3700) (0–4300)
Central America 800 200 3100 1700
(300–1300) (1700–13 400) (200–6430) (0–6100)
South America 1600 600 8000 4200
(700–2600) (0–1200) (1700–14 400) 4000–14 500)
Latin America 3700 900 13 700 5900
(1000–4100) (0–2000) (3400–24 400) (4000–24 800)
Developed countries 3000 500 10 900 6000
(1300–5000) (0–800) (0–25 800) (0–15 500)
Total 32 800 56 800 205 500 113 800
(13 400–52 100) (11 600–103 900) (44 200–326 000) (0–11 100)
Data in parentheses represent the uncertainty range (UR).
Abbreviations: EOGBS, early-onset group B Streptococcus; GBS, group B Streptococcus; IAP, intrapartum antibiotic prophylaxis; LOGBS, late-onset group B Streptococcus; NDI, neurode-
velopmental impairment. 
aStillbirths indicated a minimum estimate of cases of fetal infection.
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(UR, 8000–75 000) stillbirths, and 67 000 (UR, 12 000–123 000) 
infant deaths (Figure 7).
4. Describe GBS serotypes colonizing mothers and causing 
maternal and infant GBS disease.
Serotype III is the most dominant serotype and colonizes 28% 
of mothers worldwide. It causes 48% of EOGBS, 74% LOGBS, 
and 29% of maternal GBS disease (Figure 8). A pentavalent vac-
cine (Ia/Ib/II/III/V) would cover 96% of worldwide colonizing 
Figure  4. Cases estimated for group B streptococcal (GBS) disease in pregnant/postpartum women, fetuses, and infants in 2015, by United Nations Sustainable 
Development Goal region. *Stillbirths represent a minimum estimate of fetal infection cases. More details are shown in Supplementary Figures 4, 11, and 12.
Figure 5. Deaths estimated from group B streptococcal (GBS) disease for infants and stillbirths in 2015, by United Nations Sustainable Development Goal region. Maternal 
deaths not estimated. More details are shown in Supplementary Figures 6 and 12.
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Table 4. Stillbirth, Infant Deaths From Group B Streptococcal Disease and Resultant Disability Estimated in 2015
Region Stillbirth Early Infant Deaths Late Infant Deaths Disability
Southern Asia 9700 19 600 400 1000
(1200–21 300) (8500–34 400) (0–2800) (0–4500)
Eastern Asia 1300 3200 200 700
(0–2800) (1100–5800) (0–1600) (0–2400)
Central Asia 200 400 0 100
(0–400) (100–600) (0–200) (0–300)
Western Asia 800 2100 100 300
(0–1700) (900–10 900) (0–700) (0–1100)
South-Eastern Asia 1500 5200 200 600
(0–3300) (2100–8900) (0–1400) (0–2300)
Asia 13 400 30 400 900 2600
(1200–29 600) (12 700–60 600) (0–6600) (0–10 600)
Oceania 40 100 0 10
(0–90) (60–200) (0–30) (0–40)
Northern Africa 4000 6600 1800 1200
(1000–6700) (3100–10 900) (600–3600) (600–2100)
Southern Africa 800 1200 500 300
(200–1400) (600–1900) (100–900) (200–500)
Eastern Africa 12 600 15 600 3100 2000
(3100–21 700) (7500–26 800) (1000–6400) (1000–3600)
Western Africa 18 300 13 400 2800 1800
(4500–30 800) (5000–24 500) (800–6000) (700–3300)
Middle Africa 6300 7300 1900 1200
(1500–10 800) (3100–12 600) (600–3900) (500–2400)
Africa 42 000 44 000 10 000 6400
(10 400–71 400) (19 200–76 700) (3100–20 800) (3000–11 900)
Caribbean 100 900 100 100
(0–200) (300–1600) (0–400) (60–400)
Central America 200 800 100 200
(0–500) (100–2000) (0–600) (0–600)
South America 600 1600 300 400
(0–1200) (1400–3700) (0–1400) (60–1300)
Latin America 900 3300 400 700
(0–2000) (1900–7200) (0–2400) (100–2300)
Developed countries 500 500 200 700
(0–800) (0–1300) (0–700) (0–1700)
Total 56 800 78 400 11 500 10 500
(11 600–103 900) (32 500–138 900) (3100–30 500) (3000–26 000)
Data are presented as estimate (uncertainty range).
Table 3. Countries With the Highest Estimated Numbers of Infant Group B Streptococcal Disease Cases and Deaths
Cases Deaths
Rank Country Infant Cases Rank Country Infant Deaths
1 India 31 000 1 India 13 000
(0–75 000) (5000–23 000)
2 China 25  000 2 Nigeria 8000
(0–59 000) (2000–16 000)
3 Nigeria 22 000 3 Ethiopia 4000
(8000–39 000) (2000–8000)
4 Democratic Republic of the Congo 16 000 4 Democratic Republic of the Congo 4000
(8000–39 000) (2000–7000)
5 Egypt 14 000 5 Pakistan 3000
(8000–21 000) (1000–6000)
Data in parentheses represent the uncertainty range.
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isolates, 86% of EOGBS disease, 93% of LOGBS disease, and 
97% of maternal GBS disease. While there are a limited num-
ber of GBS capsular types (n = 10), the distribution by region 
varies, particularly for maternal GBS colonization; serotypes V, 
VI, VII, VIII, and IX are more commonly reported in South-
Eastern Asia (23%) (Supplementary Table 5).
DISCUSSION
GBS is established as a leading cause of infant disease, particu-
larly in the first week after birth, as evidenced by our estimation 
of 205 000 (UR, 101 000–327 000) neonates with EOGBS world-
wide. Furthermore, there are a minimum 33 000 (UR, 13–52 000) 
maternal GBS cases, 57 000 (UR, 12 000–104 000) fetal infec-
tions/stillbirths, and 114 000 (UR, 44 000–326 000) infants with 
LOGBS. Up to 3.5 million preterm births could be attributable to 
maternal GBS infection/colonization worldwide (Figure 9).
Importantly, GBS is also a significant cause of death, with 
57 000 (UR, 12 000–104 000) stillbirths and 90 000 (UR, 36 000–
169 000) infant deaths estimated in 2015. IAP prevented an 
estimated 3000 (UR, 0–108 000) early neonatal deaths in 2015, 
mainly in high-income contexts. A maternal GBS vaccine, 
for which candidates are in development (Table 5), with 80% 
efficacy and 90% coverage could prevent 108 000 (UR, 20 000–
198 000) fetal and infant deaths. GBS accounts for more than the 
total number of deaths from mother-to child transmission of 
human immunodeficiency virus, and more than the combined 
neonatal deaths from tetanus, pertussis, and respiratory syncy-
tial virus (Table 6), for which maternal vaccines are already in 
use, or in advanced development.
The compartmental model approach mitigates some of the 
very substantial problems with low case ascertainment for 
invasive infant disease, which can result in huge underestima-
tion, especially in low-income contexts. Our comparatively 
low estimates using infant incidence data are a result of cases 
being “missed” through lack of access to healthcare, inadequate 
clinical assessment and suspicion of infection, lack of diagnos-
tic testing, and lack of appropriate laboratory detection meth-
ods such as high-quality blood cultures (Figure  6). Sensitivity 
of microbiological cultures is further reduced if there has been 
peripartum antibiotic exposure in the mother or infant. These 
biases are not included in the uncertainty around estimates from 
incidence or prevalence data, and thus the uncertainty bounds 
are likely too narrow. In contrast, the wide uncertainty bounds 
in the compartmental model, a result of including uncertainty 
at every step, better reflect the true uncertainty in estimation of 
these outcomes. In addition, in the compartmental model we 
addressed other sources of underestimation, by adjusting mater-
nal GBS colonization for sampling site and laboratory methods 
[16] and only applying CFRs from facility data to births with a 
skilled birth attendant. Those born at home without access to a 
skilled birth attendant and who develop EOGBS will have very 
high, but unobserved, and thus unknown, CFR (Table 7). There 
are, however, limitations to the compartmental model approach, 
as described in general elsewhere [15], and in particular where 
parameters are derived from incidence data, such as the ratio of 
EOGBS to LOGBS disease. This ratio could be affected through 
differentially low case ascertainment in EOGBS compared to 
LOGBS disease or vice versa. EOGBS cases can be reduced with 
difficulties accessing care after birth and/or a high rapid CFR. 
Figure 6. Care and measurement gap estimating cases from incidence and prevalence data. Adapted from Lawn et al [15]. Triangulation of estimates from compartmental 
model compared to incidence data for invasive infant disease is detailed in Supplementary Figures 8 and 9. Abbreviation: GBS, group B Streptococcus.
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LOGBS, which more frequently is meningitis, may be differ-
entially reduced if cerebrospinal fluid sampling is infrequently 
undertaken, as is often the case in Asia [41].
In high-income contexts, reported incidence data are more 
reliable. In these countries incidence and trends can be mon-
itored, and surveillance data show that GBS remains one of 
the most important neonatal and young infant pathogens. 
The United Kingdom, the Netherlands, and France recently 
reported increases in incidence of infant disease [42–44]. In 
the era of Haemophilus influenzae type b and pneumococcal 
conjugate vaccines, GBS is now the leading cause of bacterial 
meningitis in young children in the United Kingdom and the 
United States [45, 46]. In low- and middle-income contexts, 
reported incidence data are more subject to the biases in case 
ascertainment described. However, for Africa, our estimates of 
cases of infant disease and fetal infection or stillbirth, are con-
sistent with recent reports of high incidence of GBS disease 
in facilities from Kenya and South Africa, where assessment 
and sampling recently have been systematic [47, 48]. For Asia, 
there is more uncertainty as to the burden of GBS disease. Until 
recently, the incidence of infant GBS disease was thought to be 
very low. In addition, there are no data on GBS disease in still-
birth from Asia. In our model, with a very high number of live 
births in Asia, absolute numbers of infants with EOGBS were 
high, despite the lower maternal colonization prevalence, sug-
gesting that cases are currently underestimated. For stillbirths, 
if the prevalence of GBS disease in stillbirths is comparable to 
Africa, rather than high-income contexts, the total number 
of stillbirths with GBS disease worldwide would almost dou-
ble. However, the compartmental model could overestimate 
invasive infant disease and/or stillbirth if there are biological 
differences, which it does not account for. There may be differ-
ences in virulence of GBS strains circulating in the region. GBS 
clonal complex 17 (ST17), strongly associated with serotype III, 
is hypervirulent [48, 49] and less frequently reported in Asia, 
both for maternal colonization [16] and neonatal disease [19].
Figure 7. Scenarios of estimated cases of group B streptococcal (GBS) disease and deaths prevented with different intervention methods in a year. For worldwide clinical 
risk factor screening and intrapartum antibiotic prophylaxis (IAP) where microbiological screening was in place, this estimate was applied for that country. To facilitate 
comparison between the current situation and interventions, case fatality risks have been applied as at present (ie, a higher case fatality risk for deliveries without a skilled 
birth attendant).
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Our estimates of maternal GBS disease, stillbirths, and infants 
with invasive GBS disease presenting with neonatal encepha-
lopathy are all likely to be underestimates as they are all subject 
to similar challenges for case ascertainment as infant invasive 
disease, and we were not able to include these in the compart-
mental model. Invasive GBS disease in newborns presenting 
with neonatal encephalopathy is further underestimated as the 
data derive mainly from cooling trials in high-income contexts, 
with strict case definitions (Figure 2) [22]. In addition, we do not 
attempt to measure the burden of noninvasive in utero infection, 
which may sensitize the fetus and increase the risk of neonatal 
encephalopathy (Figure 9). The challenges of estimating nonin-
vasive disease and the potential size of the unquantified burden 
are illustrated by the data on the attributable cases of preterm 
birth [21]. Even a small increase in risk of preterm birth attrib-
utable to GBS would account for many preterm births. For other 
pathogens, such as Streptococcus pneumoniae, invasive disease 
among children accounts for only 10% of all serious disease, 
with the majority (>80%) of deaths occurring from nonbacter-
emic pneumonia cases. Robust epidemiological data are critical 
Figure 9. Summary of outcomes and measurement gaps in terms of deaths and disability from group B Streptococcus (GBS) in pregnant women, stillbirths, and infants 
worldwide in 2015. More details of cases and outcomes are shown in Supplementary Figures 4, 6, 7, 10–12.
Figure 8. Group B streptococcal (GBS) serotypes colonizing mothers and causing disease in pregnant/postpartum women and infants. *Maternal colonization studies 
frequently reported Ia/Ib together, so these data are shown pooled. More details are shown in Supplementary Table 5.
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to strengthen the investment case for a GBS vaccine and to 
firmly establish the true global burden of disease [50]. Vaccine 
probe studies during phase 3 maternal vaccine trials, or postli-
censure, could also be used to contribute to our understanding 
of the total disease burden, including noninvasive disease [51].
The current mainstay of prevention against infant GBS dis-
ease is IAP, which prevented an estimated 29 000 (UR, 0–51 000) 
cases of EOGBS in 2015, mainly in high-income contexts [19]. 
IAP implementation is more common, and more feasible, in 
high-income contexts [23], because it requires a continuum 
of care, including a skilled birth attendant able to administer 
antibiotics intravenously, and with access to laboratories for a 
microbiological approach, and/or careful assessment for a clin-
ical risk factor–based approach. There is low implementation, 
or no IAP national policy where health systems have limited 
infrastructure. In addition, IAP does not target the 204 000 (UR, 
69 000–481 000) cases of maternal, fetal, and late-onset infant 
invasive infection (7–89 days). It is possible that there is some 
coincident reduction in disease with IAP, particularly in preg-
nant women [17], but it is likely administered too late in the con-
text of stillbirth [18]. In addition, IAP does not reduce maternal 
colonization, so there is no reduction in infant exposure and col-
onization, and consequent late-onset infant disease [19].
Maternal vaccination has the advantage over IAP in that it 
could leverage off existing antenatal care platforms, as success-
fully used in high-burden countries to reduce neonatal tetanus, 
where high coverage has been achieved [52]. It would also be 
expected to reduce adverse outcomes for invasive disease in preg-
nant and postpartum women, fetuses/stillbirths, and infants. A 
maternal GBS vaccine with 80% efficacy and 50% coverage would 
prevent 127 000 (63 000–282 000) infant and maternal GBS cases, 
and 60 000 (UR, 22 000–110 000) stillbirths and infant deaths. If 
coverage were increased to 90%, 229 000 (UR, 114 000–507 000) 
infant and maternal GBS cases and 108 000 (UR, 20 000–198 000) 
fetal and infant deaths could be prevented. Maternal GBS vaccina-
tion could also reduce the unquantified burden from noninvasive 
Table 5. Maternal Group B Streptococcus Vaccines in Development With Data in the Public Domain
Vaccine Candidate Manufacturer Vaccine Construct
Phase
Discovery Preclinical Phase 1 Phase 2 Program Status
NA Pfizer Multivalent CPS conjugate X Clinical program start in 2017 [55]
GBS vaccine Novartis/GSK Trivalent CPS (serotypes 
Ia, IIb, III) conjugated to 
CRM197, unadjuvanted
X Completed safety and immuno-
genicity in pregnant women. 
Study completed [27, 56–61]
NA GSK Pentavalent (Ia, Ib, II, III, V) 
CPS-CRM197
X
NA GSK Pilus proteins X
NA Biovac Polyvalent CPS conjugate X Program start in 2017
GBS-NN vaccine/ 
MVX13211
Minervax N-domains of Rib and 
Alpha C surface pro-
teins, unadjuvanted or 
Alhydrogel-adjuvanted
X Safety and immunogenicity in 
nonpregnant women. Study 
completed [26, 62, 63].
Abbreviations: CPS, capsular polysaccharide; GBS, group B Streptococcus; NA, not available.
Table  6. Comparison of Annual Estimates of Infectious Etiologies Causing Stillbirth, Infant Disease, and Death Worldwide, Including Those Where 
Maternal Vaccination Is Used or Could Be Used to Reduce This Burden
Disease Stillbirths
No. of Neonatal or Other Relevant Deaths Related to 
Maternal Infection or Nonimmunity No. of Neonatal/Infant Cases per Year
Group B Streptococcus 57 000 (12 000–103 000) 90 000a (41 000–185 000) 319 000 (119 000–417 000)
Respiratory syncytial virus Not applicable 27 300b (20 700–36 200) [64] NA
Pertussis NA 2700c,d [65] NA
Syphilis 200 000 [7] 62 000c [66] 102 000 [66]
Tetanus Not applicable 34 000c (18 000–84 000) [67] NA
HIV/AIDS 9 000 [7] 86 000e (76 000–101 000) [67] NA
Malaria 213 000 [7] NA NA
Data are presented as estimate (uncertainty range).
Abbreviations: HIV, human immunodeficiency virus; NA, no relevant estimate available.
aYoung infants (0–89 days).
bInfants (0–6 months).
cNeonates (0–27 days).
dWorld Health Organization modeling-based estimates approximately 56 700 pertussis deaths in children <5 years of age in 2015 from which the neonatal component is derived [65]. Other 
work suggests the burden could be higher, with 160 700 deaths (range, 38 000–670 000 with sensitivity analyses) in children <5 years of age [68].
eChildren <5 years of age but due to mother-to-child transmission. 
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disease, including, but not limited to, preterm birth. Several GBS 
vaccine candidates are now in active development [26] and these 
must be subject to appropriate safety and efficacy tests, but vac-
cine manufacturers are increasingly committed to investing in a 
GBS vaccine (Table 5).
There are key public health and economic considerations, to 
which these estimates contribute. These include (1) the estimated 
vaccine-preventable mortality burden; (2) the estimated scope, 
size and cost of a licensure trial; and (3) the cost-effectiveness 
of a maternal GBS vaccine, to inform policy recommendations, 
vaccine demand, and financing [51, 53, 54]. Cost-effectiveness 
models for a maternal GBS vaccine thus far have primarily con-
sidered GBS sepsis and meningitis as avertable causes of neona-
tal mortality [53]. Our estimates of the burden of GBS disease 
in pregnant and postpartum women and stillbirths, as well as 
infant disease, suggest they may be additional endpoints worthy 
of inclusion in a GBS vaccine trial.
GBS is a leading cause of invasive infection in infants, but 
GBS disease in pregnant and postpartum women and stillbirths 
is also important worldwide. GBS accounts for a far higher bur-
den of young infant mortality than other infectious diseases for 
which maternal vaccines are under development or in use, such 
as respiratory syncytial virus, pertussis, or tetanus (Table  6). 
Despite GBS accounting for only a small proportion of all still-
births, the absolute number is equal to a quarter of stillbirths 
attributed to syphilis, for which there is already a screening pro-
gram. An effective maternal GBS vaccine offers an all-encom-
passing approach to reducing GBS disease, and, as vaccination 
strategies can achieve high coverage in even the most chal-
lenging settings, it is likely to be a more equitable intervention 
than IAP. Maternal GBS vaccination has the potential to reduce 
this disease burden worldwide, within the next generation and 
including the poorest families (Table 8).
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Table 8. Key Findings and Implications
What’s new about this?
• These are the first systematic estimates of the worldwide burden of GBS and we include outcomes for pregnant and postpartum women, stillbirth, and 
infants, with later impairment. For infants this includes invasive disease, overlapping with neonatal encephalopathy, and also noting preterm birth–associ-
ated GBS as a pathway resulting in deaths and disability.
• Data gaps remain a challenge, but the compartmental model includes more national data and is less susceptible to underestimating the burden through 
low ascertainment of clinical cases, especially in low-income contexts. We have followed international estimation guidelines and data inputs and code are 
available online [28, 29].
What are the main findings?
• Cases: 319 000 (UR, 119 000–417 000) infant and 33 000 (UR, 13 000–52 000) maternal cases of GBS disease; 7000 (UR, 300–19 000) infant cases also had 
neonatal encephalopathy. Fetal infections would be at least the 57 000 (UR, 12 000–104 000) stillbirths.
• Deaths: 57 000 (UR, 12 000–104 000) stillbirths and 90 000 (UR, 36 000–169 000) infant deaths, which is more than the total number of deaths from HIV 
(mother to child transmission), or more than the combined neonatal deaths from tetanus, pertussis, and RSV (Table 6).
• Disability: >10 000 (UR, 3000–27 000) new cases of neurodevelopmental impairment per year due to infant GBS meningitis.
• Other outcomes: Up to 3.5 million cases of preterm birth attributable to GBS.
How can the data be improved?
• Geographic: more data are needed worldwide, but especially from Asia.
• Outcomes: particular gaps include maternal disease, stillbirth, impairment after infant GBS sepsis, and comorbidity with neonatal encephalopathy. Inclusion 
of GBS assessments in maternal and neonatal cause-of-death studies should be enhanced.
• Economic: cost-effectiveness modeling based on these estimates, and translation to DALYs would be a further step before undertaking economic modeling.
• Vaccine trials: standardized definitions of vaccine endpoints also enabling comparison of observational data, and informing program monitoring and evaluation.
What does it mean for policy and programs?
• Current provision of IAP prevents an estimated 29 000 (UR, 0–51 000) cases of EOGBS disease.
• Maternal vaccination: With 80% efficacy and 90% coverage could prevent 229 000 (UR, 114 000–507 000) infant and maternal GBS cases, 41 000 (UR, 
8000–75 000) stillbirths, and 67 000 (UR, 12 000–123 000) infant deaths.
Abbreviations: DALY, disability-adjusted life-year; EOGBS, early-onset group B Streptococcus; GBS, group B Streptococcus; HIV, human immunodeficiency virus; IAP, intrapartum antibiotic 
prophylaxis; RSV, respiratory syncytial virus; UR, uncertainty range. 
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Appendix: Multiple Regression Model for Maternal GBS Colonization Prevalence
Purpose: Multiple regression models are commonly used to esti-
mate the burden of diseases, particularly for a single parameter, 
eg, stillbirth rate or preterm birth rate. In the case of GBS, there 
are usually multiple outcomes that can be better estimated using 
a stable compartmental model as discussed elsewhere in this 
supplement [15]. However, we wanted to assess other approaches 
including whether a multiple regression model could be used to 
predict the national prevalence of maternal GBS colonization, 
using national-level covariates. Maternal GBS colonization prev-
alence is the parameter with the most data available to which a 
multiple regression model can be applied.
Inputs: Maternal GBS colonization prevalence data (n = 74) 
were obtained from published and unpublished literature on GBS 
worldwide, as described elsewhere in this supplement [16]. Fifteen 
national-level covariates plausibly associated with GBS coloniza-
tion prevalence were selected for possible inclusion in the model 
as predictor variables (full details in Supplementary Table 3):
log adult female obesity [34], skilled attendant at birth (SBA) 
[35], log antenatal care (4 visits), mean years female education 
[32], gross national income (GNI) [36], log neonatal mortality 
rate (NMR) [37], protected at birth against tetanus (PAB), low 
birthweight rate (LBW) [38], log general fertility rate (GFR) [39], 
log GINI coefficient [36], proportion cesarean delivery, syphilis 
index [40], United Nations region, United Nations subregion, and 
percentage population urban.
The association between potential covariates and maternal 
GBS colonization prevalence was examined using scatterplots 
(Supplementary Figure  1). Univariable analyses were under-
taken to quantify the relationship between GBS maternal colo-
nization prevalence, and continuous variables to assess if these 
predictors performed better when log transformed. Predictors 
were then assessed for retention in the model by removing one 
predictor at a time from the model (starting with the predictor 
with largest Bayesian information criterion [BIC] on univariate 
analysis), and dropping the predictor if the model was improved 
(ie, lower BIC compared to the model containing the predictor).
Model equation and fit: The equation of the final model 
resulting from the process described above was:
Log GBS prevalence a b LBW c Log GINI
d GNI e S
ij ij ij
ij
( )= + ( )+ ( )( )
+ ( )+ BA
f UNregion u e
ij
ij j ij
( )
+ ( )+ +
b(), c(), d(), and e() represent functions each involving 2 
parameters, f() indicates a 5 parameter function associ-
ated with 5 dummy variables representing different United 
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Nations regions, uj represents country-specific random effects, 
assumed to be independent normally distributed with constant 
variance, and eij represents individual data point-level residu-
als, assumed to be independent normally distributed with con-
stant variance.
We evaluated the model fit by running a series of diagnostic 
plots including analyses of regression residuals. The results from 
the diagnostic plots (Supplementary Figure 2A) and the scatter-
plot of observed vs predicted data (Supplementary Figure 2B) 
showed evidence that the model fits the data poorly.
Conclusions: This modeling approach was hampered by the 
limited number of data inputs and particularly by the lack of a 
strong relationship between available covariates and maternal 
GBS colonization.
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